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1. Introduction 
Lung cancer as the most common cancer in the world represents a major public health 
problem (1). Worldwide it has the highest rate of cancer mortality, exceeding the mortality 
rates of colorectal, breast and prostate cancers combined (2). Despite major advances in the 
treatment and management of lung cancer, most patients with lung cancer eventually die of 
this disease. Because conventional therapies have failed to make a major impact on survival, 
newer approaches are necessary in the battle against lung cancer. The poor lung cancer 
survival figures argue powerfully for new approaches to control this disease through 
chemoprevention, which has been defined as the use of agents that could reverse, suppress 
or completely halt tumor development. Developing novel mechanism-based 
chemopreventive approaches for lung cancer which humans can accept has become an 
important goal. 
Many traditional Chinese medicine (TCM) formulas have been used in cancer therapy. JIN 
formula, an ancient herbal formula from classical book JIN KUI YAO LUE (Golden 
Chamber) for the treatment of lung cancer, which is composed of Ophiopogon japonicus 
30g, Prepared Rhizoma Pinelliae15g, Ginseng radix 30g, Glycyrrhiza radix 12g, Peach 
Kernel 15g, Unprepared Coix lachryma jobi seed 30g, Chinese waxgourd seed 30g, and 
Phragmititis Caulis 30g. TCM theory regarded that lung cancer is related with both 
deficiency of Qi and Yin, or Qi insufficiency of the Spleen and Lung, as well as pathological 
changes of Qi stagnation, blood stasis, and accumulation of phlegm and toxin. Whereas, JIN 
formula could replenish both Qi and Yin, strengthen the Spleen and Lung, clear lung, 
resolve phlegm, activate blood circulation and remove stasis.  
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We extracted JIN formula with different solvents, hereafter referred to as JIN formula 
extracts (JFE). It is hypothesized that JFE may afford chemopreventive as well as 
chemotherapeutic effects against lung cancer. In the present study, we first demonstrated 
the antiproliferative effects of JFE (including E1 to E8) in A549 cells. This involves the 
tumorigenesis network of cells. Next, we determined the chemopreventive potential of JFE 
on regulation of PI3K/Akt, MAPK, NF-kB pathways in A549 and H157 human lung 
carcinoma cells. Based on the results of our in vitro data, we next carried out in vivo study 
in mice. We found that oral administration of a human acceptable dose of JIN formula (3%, 
wt/vol) to athymic nude mice implanted with A549 and H157 cells resulted in significant 
inhibition of tumor growth. 
2. Materials and methods 
2.1 Materials 
Akt, JNK, and p38 antibodies were obtained from Cell Signaling Technology. The polyclonal 
antibodies NF-kB/p65, ERK1/2 were procured from Santa Cruz Biotechnology Inc. Anti-
mouse and anti-rabbit secondary antibody horseradish peroxidase (HRP) conjugate was 
obtained from Amersham Life Science Inc.  
2.2 Methods 
2.2.1 Preparation of JFE 
Fresh JIN formula was decocted in distilled water. As shown in Figure 1, different solvents 
were applied to acquire the following eight extracts: Water extraction concentrate (E1), 
Ethanol precipitation (E2), Precipitates in ethanol recovery (E3), Ethanol concentration (E4), 
Cyclohexane extract (E5), Ethyl acetate extract (E6), N-butanol extract (E7) and Water 
solution (E8). The extracts were condensed and freeze dried. The freeze-dried extracts were 
stored at 4°C to be used for various treatments. 
2.2.2 Cell culture and treatment 
The human lung carcinoma A549 and H157 cells were obtained from American Type 
Culture Collection and cultured in DMEM medium, supplemented with 10% fetal bovine 
serum, 1% penicillin/streptomycin (P-S) in a 5% CO2 atmosphere at 37°C. The extracts were 
dissolved in dimethyl sulfoxide (DMSO) and were used for the treatment of cells. A total of 
50–60% confluent cells were treated with the extracts (1–100 µg/ml) for 72 h in complete 
growth medium. 
2.2.3 Cell viability (MTT assay) 
The effect of JFE on the viability of cells was determined by 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyl tetrazoliumbromide assay. The cells were plated at 1×104cells/well in 200 µl of 
complete culture medium containing 1–100 µg/ml concentrations of JFE in 96-well 
microtiter plates for 72 h. After incubation for specified times at 37°C in a humidified 
incubator, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazoliumbromide (5 mg/ml in PBS) 
was added to each well and incubated for 4 h, after which the plate was centrifuged at 1800g 
for 5 min at 4°C. The absorbance was recorded on a microplate reader at the wavelength of 
540 nm. The effect of JFE on growth inhibition was assessed as percent cell viability where 
DMSO-treated cells were taken as 100% viable. DMSO at the concentrations used was 
without any effect on cell viability. 
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Fig. 1. The Extracting Procedure of JIN formula 
2.2.4 Protein extraction and western blotting 
Following the treatment of cells as described above, the media was aspirated, the cells were 
washed with cold PBS (pH 7.4), and ice-cold lysis buffer (50 mM Tris–HCl, 150 mM NaCl, 1 
mM EGTA, 1 mM EDTA, 20 mM NaF, 100 mM Na3VO4, 0.5% NP-40, 1%Triton X-100, 1 mM 
PMSF (pH 7.4) with freshly added protease inhibitor cocktail (Protease Inhibitor Cocktail Set 
III; Calbiochem) over ice for 30 min. The cells were scraped and the lysate was collected in a 
microfuge tube and passed through needle to break up the cell aggregates. The lysate was 
cleared by centrifugation at 14 000g for 15 min at 4°C and the supernatant (whole cell lysate) 
was used or immediately stored at -80°C.  
For western blotting, 30-50 mg protein was resolved over 8-12% polyacrylamide gels and 
transferred to a nitrocellulose membrane. The blot was blocked in blocking buffer (5% non-
fat dry milk/1% Tween 20; in 20 mM TBS, pH 7.6) for 1 h at room temperature, incubated 
with appropriate monoclonal or polyclonal primary antibody in blocking buffer for 1.5 
hours to overnight at 4°C, followed by incubation with anti-mouse or anti-rabbit secondary 
antibody HRP conjugate obtained from Amersham Life Science Inc. Densitometric 
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measurements of the band detected by chemiluminescence in western blot analysis were 
performed using digitalized scientific software program Quantity One. 
2.2.5 In vivo tumor xenograft model 
Balb/c athymic (nude) mice (male, 6−8 weeks) weighing 21−25 g were purchased from 
Animal Center, Academy of Military Medical Sciences, (Beijing, China) and were housed 
under specific pathogen-free conditions according to the guidelines of Animal Care, Nanjing 
University of Chinese Medicine. The animal room was controlled for temperature (22 ±2°C), 
light (12 hour light/dark cycle) and humidity (50±10%). All laboratory feed pellets and 
bedding was autoclaved. 
The tumor regression model in nude mice has been successfully applied to evaluate 
antitumor activity. This model was therefore used to evaluate suppression of solid tumor 
growth in JIN Formula (JIN). A total of 1×107 A549, H157 cells in 0.2 ml culture medium 
were injected subcutaneously into the flank of each mouse using a 26-gauge needle. After 7 
days observation, an apparently solid tumor mass was excised from mice inoculated with 
lung cancer cells. When the tumor volume reached about 50 mm3 in the nude mice, 
xenografted tumor model were randomly distributed into normal group, model group, Jin 
group, after sacrifice of animals with oral administration of JIN formula (3%, wt/vol) for 16 
days, tumor inhibiting rate was recorded to show the effects of drugs on tumor growth. 
Tumor inhibiting rate= (average of tumor weight in model group-average of tumor weight 
in JIN group) /average of tumor weight in model group ×100%. 
2.3 Statistical analysis 
Results were analyzed using a two-tailed Student’s t-test to assess statistical significance and 
P-values<0.05 were considered significant.  
3. Result 
3.1 Inhibition of cell growth by JFE in A549 cells 
This study was designed to show the chemopreventive/chemotherapeutic potential of JIN 
formula against lung cancer. Initially in our study, we investigated the antiproliferative 
effects of JFE treatment on human lung carcinoma A549 cells. Therefore, using A549 cells, 
we first evaluated the effect of JFE on the growth of these cells by MTT assay. We compared 
the antiproliferative effects of JFE (including E1 to E8) on A549 cells. As shown in Figure 2, 
treatment of JFE (1–100 µg/ml) for 72 h was found that E6 and E7 could decrease the 
viability of A549 cells.  
3.2 Inhibition of tumorigenesis pathways by JFE in A549 and H157 cells 
To explore the mechanism of antiproliferative effects of JIN formula against lung cancer, we 
investigated the involvement of Akt, ERK1/2, JNK1/2, p38 and NF-κB machinery during 
the inhibition of tumorigenesis by JFE in A549 and H157 cells.  
Akt, also known as protein kinase B, which is a serine or threonine kinase, has been 
identified as an important component of tumorigenesis signaling pathway. The PI3K/Akt 
promotes cell survival by activating the NF-kB signaling pathway (3). Studies have shown 
that Akt plays an important role in carcinogenesis. We first investigated the effect of JFE on 
Akt protein expression in human lung carcinoma cells. In our study, we have demonstrated 
that the treatment of A549 and H157 cells with JFE (E1–E8) resulted in different degree 
inhibition of Akt pathways on tumor promotion processes as shown in Figure 3. 
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Fig. 2. The effects of JFE (including E1 to E8) on A549 cells growth 
The MAP kinase superfamily (MAPKs) has been characterized into three groups which 
include extracellular signal-regulated kinase p44/42 (ERK), JNK/SAPK (c-jun N-terminal 
kinase/stress activated protein kinase) and p38 MAP kinase. MAPKs, a group of 
serine/threonine-specific, proline-directed protein kinases are known to modulate 
transcription factor activities. (4, 5). The involvement of the MAPK pathway in tumor 
proliferation is well documented. Transient activation of ERK is responsible for proliferation 
and differentiation and has also been shown to be involved in tumor promotion processes 
(3). Stimulation of JNK/SAPK and p38 can mediate differentiation, inflammatory responses 
and cell death (6). In the present study, we assessed the effect of JFE on MAPK pathway in 
A549 and H157 human lung carcinoma cells. The immunoblot analysis demonstrated that 
the treatment of cells with JFE inhibited ERKl/2, JNK1/2 and p38 proteins, and this 
inhibition of JNK1/2 and p38 in A549 cells was stronger than in H157 (Figure 3). Several 
studies have shown that JNK pathway plays a major role in cellular function, such as cell 
proliferation and transformation, whereas the ERK pathway suppresses apoptosis and 
enhances cell survival or tumorigenesis (4). ERK1/2 and p38 are also involved in the 
transcriptional activation of NF-kB (7, 8). 
NF-kB is a sequence specific transcription factor that is known to be involved in the 
inflammatory and innate immune responses (9, 10). NF-kB is sequestered in the cytoplasm in 
an inactive form through interaction with IkB. Phosphorylation of IkB by IkB kinase (IKK) 
causes ubiquitination and degradation of IkB, thus releasing NF-kB which then translocates to 
the nucleus, where it binds to specific kB binding sites in the promoter regions of several genes 
(11). Studies have shown that NF-kB activation plays an important role in cell survival, by its 
ability to block or reduce apoptosis (12). In the present study, we further investigated the effect 
of JFE on the pattern of NF-kB activation and whether treatment with JFE inhibits nuclear 
translocation of NF-kB/p65 in A549 and H157 cells. As is evident from western blot analysis 
data and the relative density of bands, we found that JFE (E2, E3, E7) treatment of A549 cells 
resulted in inhibition of translocation of NF-kB/p65, meanwhile, we demonstrated that NF-kB 
is activated in H157 human lung carcinoma cells treated with JFE (E2, E3, E7) and is 
translocated to the nucleus when measured by western blot analysis (Figure 3). 
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Fig. 3. (A) Inhibitory effects of JFE on tumorigenesis pathways in human lung carcinoma 
A549 cells (B) Inhibitory effects of JFE on tumorigenesis pathways in human lung carcinoma 
H157cells 
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The immunoblot analysis demonstrated that JFE (E1–E8) treatment could induce (i) 
inhibition of AKt, (ii) inhibition of ERK1/2 (p44 and p42), (iii) inhibition of JNK1/2 (p54 and 
p46), (iv) inhibition of p38 protein and (v) regulation of NF-kB. 
3.3 Inhibition on the growth of human lung carcinoma A549 and H157 cells by JIN 
formula in nude mice 
JFE inhibits the development of lung tumorigenesis by modulating and inhibiting 
PI3K/Akt, MAPK, and NF-kB signaling. To establish the relevance of these in vitro findings 
to in vivo situation, athymic nude mice were implanted with human lung carcinoma A549 
and H157 cells. Compared with model group, Jin formula could significantly inhibit volume 
growth of A549 and H157 xenografted tumors. The inhibiting rate could reach to 28.5% and 
25% in A549 and H157 tumor-bearing mice respectively (p＜0.05). We found that the oral 
administration of JIN formula significantly slowed the progression of A549 and H157 tumor 
growth in nude mice.  
4. Discussion 
Lung cancer as the most common cancer in the world represents a major public health 
problem. Worldwide it accounts for 1.18 million cancer-related deaths and is the most 
common cause of cancer death in both men and women (13). Lung carcinogenesis is a chronic 
and multistep process resulting in malignant lung tumors. This progression from normal to 
neoplastic pulmonary cells or tissues could be arrested or reversed through pharmacological 
treatments. These therapeutic interventions should reduce or avoid the clinical consequences 
of lung cancer by treating early neoplastic lesions before the development of clinically evident 
signs or symptoms of malignancy. Preclinical, clinical and epidemiological findings relating to 
different classes of candidate chemopreventive agents provide strong support for lung cancer 
prevention as a therapeutic strategy (14). Cancer chemoprevention is an attractive approach to 
reduce lung cancers by treating early steps in lung carcinogenesis. There is a convergence of 
basic scientific and clinical findings in lung cancer chemoprevention. Pharmacological 
interventions also can be used to reverse or arrest the progression of lung carcinogenesis. For 
this reason, additional clinical trials are needed that emphasize a mechanistic approach in 
which mechanisms identified in vitro can be validated in vivo. 
This study was designed to show the chemopreventive/chemotherapeutic potential of JIN 
formula against lung cancer. we assessed the efficacy of the JIN formula, which is an ancient 
herbal formula from classical book JIN KUI YAO LUE (Golden Chamber) for the treatment 
of lung cancer and explored its probable molecular mechanisms. Initially, employing human 
lung carcinoma A549 cells, we compared the growth inhibitory effects of JIN formula 
extracts (JFE，including E1 to E8). The results showed that E6 and E7 could decrease the 
viability of A549 cells by the MTT assays. To explore the mechanism of antiproliferative 
effects of JIN formula against lung cancer, we investigated the involvement of Akt, ERK1/2, 
JNK1/2, p38 and NF-κB pathway during the inhibition of tumorigenesis by JFE in A549 and 
H157 cells. The immunoblot analysis demonstrated that JFE treatment could result in 
different degree inhibition of above signaling pathways on tumor promotion processes. Oral 
administration of JIN formula (3%, wt/vol) to athymic nude mice implanted with A549 and 
H157 cells resulted in a significant inhibition in tumor growth. 
In conclusion, the present study demonstrates that human non small cell lung cancer A549 and 
H157 cells are highly sensitive to JIN formula both in vitro and in vivo experimental models. 
JIN formula inhibits the development of lung tumorigenesis by modulating the imbalance of 
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proliferative and apoptotic signaling network. Based on the present study it is tempting to 
suggest that JIN formula and its effective extracts have strong potential for development as a 
chemopreventive and possibly as a chemotherapeutic agent against lung cancer. 
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